Loading data for ORMP — first visit, this takes a few seconds.

Alerte

Oramed Pharmaceuticals In... (ORMP)

NasdaqCM: ORMP · Prix en temps réel · USD

4.78

+0.21 (4.60%)

À la clôture : Aug 19, 2026, 2:22 PM

4.60% (1D)

Aucune donnée disponible

Cours acheteur	3.4
Capitalisation boursière	201.12M
Chiffre d’affaires (ttm)	n/a
Résultat net (ttm)	174.06M
Bêta	1.16
EPS (ttm)	4.13
Ratio P/E (ttm)	1.17
P/E prévisionnel	-60.44
P/B (ttm)	0.63
P/S (ttm)	n/a
Earnings Date	Nov 12, 2026

Cours vendeur	5.78
Volume	297,698
Volume moy. (20D)	292,669
Ouverture	4.56
Clôture précédente	4.57
Fourchette du jour	4.48 - 4.82
Intervalle de 52 semaines	2.05 - 5.19
Analyste	n/a
Objectif de prix	n/a
Dividendes	$0.25 (5.22%)
Date ex-dividende	16 janv. 2026

À propos de ORMP

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporat...

[En savoir plus]

Industrie Biotechnology

Secteur Healthcare

Date d’introduction May 1, 2007

Employés n/a

Bourse NasdaqCM

Symbole boursier ORMP

Site web https://oramed.com

Profil complet de l’entreprise

Performance financière

En 2025, le chiffre d’affaires de Oramed Pharmaceuticals s’élevait à 2M, soit une hausse de undefined% par rapport aux 0 de l’année précédente. Le bénéfice s’élevait à 64.05M, soit une baisse de -436.04%.

États financiers

Surprise sur les résultats

Oramed Pharmaceuticals a publié ses résultats trimestriels le Aug 10, 2026 :

Chiffre d’affaires de $0 est inférieur aux estimations de $0, avec -100.00% Baisse en glissement annuel.

EPS de 1.84 dépasse les estimations de 1.41, avec 1068.42% croissance en glissement annuel.

Prochaine publication des résultats

Oramed Pharmaceuticals Inc. devrait publier ses résultats le Nov 12, 2026, pendant les heures de marché.
Les analystes prévoient un chiffre d’affaires de ... Passer à l’offre supérieure

Actualités

2 mois il y a · Simply Wall St.

June 2026 Penny Stocks To Watch For Potential Growth

Over the last 7 days, the market has remained flat, but it is up 24% over the past year, with earnings expected to grow by 19% per annum over the next few years. For investors willing to explore beyon...

3 mois il y a · Simply Wall St.

Spotlight On Oramed Pharmaceuticals And Two Other Prominent Penny Stocks

The market has climbed 1.5% in the last 7 days and is up 26% over the last 12 months, with earnings forecast to grow by 17% annually. While the term 'penny stock' might seem outdated, these investment...

4 mois il y a · Simply Wall St.

Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors

The market has shown impressive growth, with a 4.2% increase over the last week and a 29% rise over the past year, while earnings are projected to grow by 16% annually. Although the term 'penny stock'...

4 mois il y a · Associated Press Finance

Oramed: Q4 Earnings Snapshot

NEW YORK (AP) — Oramed Pharmaceuticals Inc. ORMP) on Thursday reported profit of $10 million in its fourth quarter. The New York-based company said it had net income of 24 cents per share.

6 mois il y a · Motley Fool

CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround

CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.

Page 1 de 2